Insider Transactions in Q3 2025 at Day One Biopharmaceuticals, Inc. (DAWN)
Insider Transaction List (Q3 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 18
2025
|
Charles N York Ii COO and CFO |
SELL
Open market or private sale
|
Direct |
4,106
-1.46%
|
$24,636
$6.77 P/Share
|
|
Aug 18
2025
|
Lauren Merendino Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,766
-8.24%
|
$22,596
$6.77 P/Share
|
|
Aug 18
2025
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
16,058
-9.05%
|
$96,348
$6.77 P/Share
|
|
Aug 18
2025
|
Adam Dubow Gen Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
4,365
-7.37%
|
$26,190
$6.77 P/Share
|
|
Aug 15
2025
|
Charles N York Ii COO and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,875
+1.5%
|
-
|
|
Aug 15
2025
|
Lauren Merendino Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,536
+7.72%
|
-
|
|
Aug 15
2025
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
31,686
+4.52%
|
-
|
|
Aug 15
2025
|
Adam Dubow Gen Counsel & Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
12,087
+5.23%
|
-
|
|
Jul 10
2025
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
BUY
Bona fide gift
|
Indirect |
402,057
+10.49%
|
-
|
|
Jul 10
2025
|
Jeremy Bender CHIEF EXECUTIVE OFFICER |
SELL
Bona fide gift
|
Indirect |
601,259
-76.55%
|
-
|